| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q2 2022 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Tandem Diabetes, Inc. | 5 | Q3 2021 | 86.2% |
| Karyopharm Therapeutics, Inc. | 5 | Q3 2021 | 34.2% |
| Calithera Biosciences, Inc. | 5 | Q3 2021 | 10.9% |
| Mereo BioPharma Group PLC | 5 | Q3 2021 | 0.7% |
| Senseonics Holdings, Inc. | 3 | Q1 2021 | 18.0% |
View Delphi Management Partners VIII, L.L.C.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2021-11-15 |
| 13F-HR | 2021-08-12 |
| 13F-HR | 2021-05-17 |
| 13F-HR | 2021-02-08 |
| 13F-HR | 2020-02-07 |
| 4 | 2016-03-23 |
| 3 | 2016-03-17 |
| 4 | 2016-02-05 |
| 4 | 2014-10-09 |
| 3 | 2014-10-01 |
View Delphi Management Partners VIII, L.L.C.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.